NO20054767L - Sammensetninger omfattende apomorfin for inhalering i lunge - Google Patents

Sammensetninger omfattende apomorfin for inhalering i lunge

Info

Publication number
NO20054767L
NO20054767L NO20054767A NO20054767A NO20054767L NO 20054767 L NO20054767 L NO 20054767L NO 20054767 A NO20054767 A NO 20054767A NO 20054767 A NO20054767 A NO 20054767A NO 20054767 L NO20054767 L NO 20054767L
Authority
NO
Norway
Prior art keywords
apomorphine
formulations
compositions
present
sexual dysfunction
Prior art date
Application number
NO20054767A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054767D0 (no
Inventor
John Nicholas Staniforth
David Morton
Michael Tobyn
Stephen Eason
Quentin Harmer
David Ganderton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/413,022 external-priority patent/US20040204439A1/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20054767D0 publication Critical patent/NO20054767D0/no
Publication of NO20054767L publication Critical patent/NO20054767L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20054767A 2003-04-14 2005-10-17 Sammensetninger omfattende apomorfin for inhalering i lunge NO20054767L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/413,022 US20040204439A1 (en) 2003-04-14 2003-04-14 Composition, device, and method for treating sexual dysfunction via inhalation
US10/621,964 US20040204440A1 (en) 2003-04-14 2003-07-17 Composition, device, and method for treating sexual dysfunction via inhalation
PCT/GB2004/001627 WO2004089374A1 (en) 2003-04-14 2004-04-14 Pharmaceutical compositions comprising apomorphine for pulmonary inhalation

Publications (2)

Publication Number Publication Date
NO20054767D0 NO20054767D0 (no) 2005-10-17
NO20054767L true NO20054767L (no) 2005-12-21

Family

ID=33161980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054767A NO20054767L (no) 2003-04-14 2005-10-17 Sammensetninger omfattende apomorfin for inhalering i lunge

Country Status (9)

Country Link
US (1) US20060178394A1 (pt)
EP (1) EP1613323A1 (pt)
JP (1) JP2006522785A (pt)
AU (1) AU2004228757A1 (pt)
BR (1) BRPI0409380A (pt)
CA (1) CA2522231A1 (pt)
NO (1) NO20054767L (pt)
RU (1) RU2364400C2 (pt)
WO (1) WO2004089374A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
AU2006228296B2 (en) * 2005-03-28 2011-08-04 Orexo Ab New pharmaceutical compositions useful in the treatment of Parkinson's disease
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
MA42268A (fr) * 2015-06-23 2018-05-02 Axim Biotechnologies Inc Compositions antimicrobiennes contenant des cannabinoïdes
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US20170071248A1 (en) * 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
ES2988939T3 (es) 2016-07-08 2024-11-22 Trudell Medical Int Inc Dispositivo de presión espiratoria positiva oscilante inteligente
DE202017007545U1 (de) 2016-12-09 2022-09-01 Trudell Medical International Intelligenter Vernebler
EP4585247A3 (en) 2018-01-04 2025-07-23 Trudell Medical International Inc. Smart oscillating positive expiratory pressure device
WO2021038467A1 (en) 2019-08-27 2021-03-04 Trudell Medical International Smart oscillating positive expiratory pressure device
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
DE69732306T2 (de) * 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
AU4982300A (en) * 1999-05-06 2000-11-21 Pentech Pharmaceuticals, Inc. Regimen and kit for amelioration of premature ejaculation
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
JP2001072586A (ja) * 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
KR20030036157A (ko) * 2000-04-07 2003-05-09 탭 파마슈티칼 프로덕츠 인코포레이티드 아포모르핀 유도체 및 이의 사용 방법
US6948494B1 (en) * 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
IL155667A0 (en) * 2000-11-15 2003-11-23 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20020086876A1 (en) * 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2002184831A (ja) * 2000-12-11 2002-06-28 Hirata Corp Foupオープナ
WO2003026631A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation

Also Published As

Publication number Publication date
JP2006522785A (ja) 2006-10-05
NO20054767D0 (no) 2005-10-17
CA2522231A1 (en) 2004-10-21
EP1613323A1 (en) 2006-01-11
AU2004228757A1 (en) 2004-10-21
WO2004089374A1 (en) 2004-10-21
RU2005135133A (ru) 2006-06-10
RU2364400C2 (ru) 2009-08-20
US20060178394A1 (en) 2006-08-10
BRPI0409380A (pt) 2006-04-18

Similar Documents

Publication Publication Date Title
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
MEP30108A (en) Formoterol superfine formulation
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
EA201100305A1 (ru) Лечение респираторных заболеваний
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
BR0311451A (pt) Composição tamponada de nicotina lìquida para administração pulmonar
NO20072920L (no) Kombinasjon av metylxantinforbindelser og steroider for a behandle kroniske respirasjonssykdommer
WO2010068754A3 (en) Methods and compositions for delivery of medicaments to the lungs
NO20063693L (no) Forbindelse og metode for anvendelse
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
MX2007004495A (es) Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
NZ587561A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
NO20063047L (no) Vandige ciclesonidsuspensjoner for forstoving
BRPI0409380A (pt) composições farmacêuticas
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
UA86807C2 (ru) ПОРОШКОВАЯ КОМПОЗИЦИЯ ДЛЯ ИНГАЛЯЦИИ, КОТОРАЯ СОДЕРЖИТ ЭНАНТИОМЕРНО ЧИСТЫЕ β-АГОНИСТЫ
SE0400378D0 (sv) Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application